Wells Fargo raised the firm’s price target on RxSight to $45 from $42 and keeps an Overweight rating on the shares. RxSight reported preliminary Q4 revenue that beat consensus estimates, with upside in LDD and LAL volume, and 024 guidance was also ahead of expectations, the analyst tells investors in a research note.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on RXST:
- RxSight, Inc. Announces Preliminary Unaudited Fourth Quarter and Full-Year 2023 Financial and Operational Results and 2024 Guidance
- RxSight, Inc. to Present at the J.P. Morgan Healthcare Conference
- RxSight price target raised by $7 at BTIG, here’s why
- RxSight price target raised to $43 from $36 at BTIG
- Microsoft initiated, Hertz downgraded: Wall Street’s top analyst calls
